I

Investigate MD | Scottsdale, AZ

Research site
(Unclaimed)
Location
20201 North Scottsdale Healthcare Drive, Suite 270, Scottsdale, Arizona, United States of America
Site insights

Top conditions

Alopecia Areata (5 trials)

Alopecia (5 trials)

Dermatitis (4 trials)

Eczema (4 trials)

Atopic Dermatitis (4 trials)

Top treatments

LY3009104
STP705
Baricitinib
MT10109L
RIST4721
Clascoterone
Etrasimod
Sofpironium Bromide

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

4 of 18
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata (BRAVE-AA2)

The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).

Active, not recruiting
Alopecia Areata
Drug: Baricitinib
Drug: Placebo

The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hai...

Enrolling
Hair Diseases
Alopecia
Drug: Baricitinib
Drug: Placebo

The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and...

Enrolling
Alopecia, Androgenetic
Drug: Clascoterone 5% solution
Drug: Vehicle solution

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

Trial sponsors

Lilly logo

Lilly (5 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems